Report from the pancreatic ductal adenocarcinoma disease focused panel
- 114 Downloads
Listing of all panel members
Avinash Kambadakone (Co-Chair)
Eric Tamm (Co-Chair)
Zhen Jane Wang
Look back (most significant science/advances in field in past year)
The following are some of the more major advances in pancreatic cancer in 2018–2019.
Increasingly widespread use of testing for germline genetic changes, such as BRCA2. Patients with BRCA2 have a higher risk for developing cancers of the pancreas, prostate, breast, and ovaries, but are also notably more responsive to drugs such as PARP inhibitors and platinum-based therapies. Patients with a combination of mismatch repair deficiencies and microsatellite instability-high may respond to pembrolizumab. Current NCCN guidelines now recommend routine genetic testing for...
- 1.Tempero MA (2019) NCCN Guidelines Updates: Pancreatic Cancer. 17: 603Google Scholar
- 2.National Cancer Institute (2019) Advances in Pancreatic Cancer Research. retrieved: 09/06/2019; Available from: https://www.cancer.gov/types/pancreatic/research.
- 3.O’Hara MH, O’Reilly EM, Rosemarie M, et al (2019) Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Cancer Research 79: CT004-CT004Google Scholar
- 4.National Comprehensive Cancer Network (2019) Pancreatic Adenocarcinoma (Version 3.2019). retrieved: 09/06/2019; Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.